Joaquin Cigarroa, M.D., notes it’s important to consider patient preferences at an FDA committee meeting with manufacturers about renal denervation, a device-based hypertension treatment.
OHSU research finds 45 percent of Oregonians who died in 2015 and 2016 had a Physician Order for Life-Sustaining Treatment, with editorial noting POLST’s increased usage.